AR074409A1 - Derivados de arilciclohexileteres de 5,6-dihidro-4h-2,3,5,10-b-tetraaza-benzo[e]azuleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en disfunciones sexuales y trastornos del snc, entre otras patologias. - Google Patents
Derivados de arilciclohexileteres de 5,6-dihidro-4h-2,3,5,10-b-tetraaza-benzo[e]azuleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en disfunciones sexuales y trastornos del snc, entre otras patologias.Info
- Publication number
- AR074409A1 AR074409A1 ARP090104565A ARP090104565A AR074409A1 AR 074409 A1 AR074409 A1 AR 074409A1 AR P090104565 A ARP090104565 A AR P090104565A AR P090104565 A ARP090104565 A AR P090104565A AR 074409 A1 AR074409 A1 AR 074409A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- halogen
- cyano
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 title 1
- 230000004064 dysfunction Effects 0.000 title 1
- 230000001568 sexual effect Effects 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 206010001488 Aggression Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000012761 aggressive behavior Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Los compuestos de la invención actúan como moduladores del receptor de la VIa y en particular como antagonistas del receptor de la VIa; la invención se refiere además a su obtención, a composiciones farmacéuticas que los contienen y a su utilización como medicamentos. Los compuestos activos de la presente invención son útiles como agentes terapéuticos que actúan a nivel periférico y central en los estados patológicos tales como la dismenorrea, disfunción sexual masculina o femenina, hipertensión, fallo cardíaco crónico, secreción inapropiada de vasopresina, cirrosis hepática, síndrome nefrótico, ansiedad, trastornos depresivos, trastorno obsesivo-compulsivo, trastornos de espectro autista, esquizofrenia y comportamiento agresivo. Reivindicación 1: El compuesto de la fórmula general (1) en la que R1 es arilo o heteroarilo, sin sustituir o sustituido por uno o más sustituyentes elegidos con independencia entre A; R2 es H, alquilo C1-12, sin sustituir o sustituido por uno o más OH, halógeno, ciano o alcoxi C1-12, -(CH2)q-Ra, en el que Ra es fenilo o un heteroarilo de 5 ó 6 eslabones, cada uno de ellos está sin sustituir o sustituido por uno o más sustituyentes elegidos con independencia entre A, -(CH2)rNRiRii, -C(O)-alquilo C1-12, dicho alquilo C1-12 está sin sustituir o sustituido por uno o más OH, halógeno, ciano o alcoxi C1-12, -C(O)(CH2)qOC(O)-alquilo C1-12, -C(O)(CH2)qNRiRii, -C(O)O-alquilo C1-12, dicho alquilo está sin sustituir o sustituido por uno o más OH, halógeno, ciano o alcosi C1-12, -S(O)2-alquilo C1-12, -S(O)2NRiRii, Ri y Rii con independencia entre sí son H, alquilo C1-12, o junto con el nitrógeno, al que están unidos, forman un heterocicloalquilo de 3 a 7 eslabones que contiene uno o dods heteroátomos elegidos entre N, O y S, dicho heterocicloalquilo está sin sustituir o sustituido por uno o más sustituyentes elegidos por independencia entre B, q es el número 1, 2, 3 ó 4; r es el número 2, 3 ó 4, A es halógeno, ciano, OH, alquilo C1-7, haloalquilo C1-7, alcoxi C1-7, haloalcoxi C1-7 o hidroxi-alquilo C1-7, B es oxo, halógeno, OH, alquilo C1-7 o alcoxi C1-7, R3 es Cl o F, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08170188 | 2008-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074409A1 true AR074409A1 (es) | 2011-01-12 |
Family
ID=41382009
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104565A AR074409A1 (es) | 2008-11-28 | 2009-11-26 | Derivados de arilciclohexileteres de 5,6-dihidro-4h-2,3,5,10-b-tetraaza-benzo[e]azuleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en disfunciones sexuales y trastornos del snc, entre otras patologias. |
| ARP180101972 AR112338A2 (es) | 2008-11-28 | 2018-07-16 | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101972 AR112338A2 (es) | 2008-11-28 | 2018-07-16 | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8227458B2 (es) |
| EP (1) | EP2370441B1 (es) |
| JP (1) | JP5452608B2 (es) |
| KR (1) | KR101359742B1 (es) |
| CN (1) | CN102227428B (es) |
| AR (2) | AR074409A1 (es) |
| AU (1) | AU2009319123B2 (es) |
| BR (1) | BRPI0922303B1 (es) |
| CA (1) | CA2743976C (es) |
| CO (1) | CO6341478A2 (es) |
| CR (1) | CR20110220A (es) |
| CY (1) | CY1115435T1 (es) |
| DK (1) | DK2370441T3 (es) |
| EC (1) | ECSP11011089A (es) |
| ES (1) | ES2431279T3 (es) |
| HR (1) | HRP20131067T1 (es) |
| IL (1) | IL212122A (es) |
| MA (1) | MA32781B1 (es) |
| MX (1) | MX2011005596A (es) |
| MY (1) | MY150837A (es) |
| NZ (1) | NZ592076A (es) |
| PE (1) | PE20110582A1 (es) |
| PL (1) | PL2370441T3 (es) |
| PT (1) | PT2370441E (es) |
| RU (1) | RU2507205C2 (es) |
| SG (1) | SG171846A1 (es) |
| SI (1) | SI2370441T1 (es) |
| TW (1) | TWI379833B (es) |
| UA (1) | UA103504C2 (es) |
| WO (1) | WO2010060836A1 (es) |
| ZA (1) | ZA201103419B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8952037B2 (en) | 2010-05-13 | 2015-02-10 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
| US8828989B2 (en) * | 2011-09-26 | 2014-09-09 | Hoffmann-La Roche Inc. | Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists |
| MX2014003600A (es) * | 2011-10-05 | 2014-04-25 | Hoffmann La Roche | Ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas v1a. |
| CN105492010B (zh) | 2013-08-19 | 2020-01-03 | 豪夫迈·罗氏有限公司 | 用于治疗相移睡眠障碍的V1a拮抗剂 |
| HRP20210966T1 (hr) | 2013-12-05 | 2021-09-17 | F. Hoffmann - La Roche Ag | Sinteza trans-8-kloro-5-metil-1-[4-(piridin-2-iloksi)-cikloheksil]-5,6-dihidro-4h-2,3,5,10b-tetraazabenzo[e]azulena i njegovih kristalnih oblika |
| WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
| RU2666598C1 (ru) * | 2017-07-14 | 2018-09-11 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Средство для коррекции расстройств аутистического спектра |
| US11033601B2 (en) | 2017-09-14 | 2021-06-15 | The Regents Of The University Of Colorado, A Body Corporate | Selective inhibition of V1b for treating fatty liver |
| TWI816718B (zh) * | 2017-12-08 | 2023-10-01 | 瑞士商赫孚孟拉羅股份公司 | 醫藥調配物 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| WO2020139670A1 (en) | 2018-12-27 | 2020-07-02 | Teva Pharmaceuticals International Gmbh | Solid state forms of balovaptan |
| EP4185570B1 (en) * | 2020-07-23 | 2024-10-09 | F. Hoffmann-La Roche AG | Cyclohexyl substituted triazoles as vasopressin receptor v1a antagonists |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
| PL205704B1 (pl) * | 1999-01-19 | 2010-05-31 | Ortho Mcneil Pharm Inc | Związki tricyklicznej benzodiazepiny, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie |
| TWI239333B (en) * | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| US7022699B2 (en) | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| GB0303852D0 (en) | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| GB0400700D0 (en) * | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| KR100840852B1 (ko) | 2004-05-25 | 2008-06-23 | 화이자 프로덕츠 인크. | 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체 |
| JP4069159B2 (ja) * | 2004-05-25 | 2008-04-02 | ファイザー・プロダクツ・インク | テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ |
| EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| WO2006021882A1 (en) * | 2004-08-25 | 2006-03-02 | Pfizer Limited | Triazolobenzodiazepines and their use as vasopressin antagonists |
| EP1877399A1 (en) | 2005-04-26 | 2008-01-16 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| WO2006123242A1 (en) | 2005-05-18 | 2006-11-23 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| ES2376378T3 (es) | 2007-01-12 | 2012-03-13 | F. Hoffmann-La Roche Ag | Derivados de espiropiperidina-glicinamida. |
| KR101159060B1 (ko) * | 2008-04-09 | 2012-07-03 | 가부시키가이샤 구라레 | 가스 배리어성 적층체 및 이의 제조방법 |
| PL2356123T3 (pl) | 2008-11-13 | 2013-03-29 | Hoffmann La Roche | Spiro-5,6-dihudro-4h-2,3,5,10b- tetraazabenzo[e]azuleny |
| KR101385433B1 (ko) * | 2008-11-18 | 2014-04-14 | 에프. 호프만-라 로슈 아게 | 다이하이드로테트라아자벤조아줄렌의 알킬사이클로헥실에터 |
| US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) * | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8492376B2 (en) * | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8481528B2 (en) * | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
-
2009
- 2009-11-18 DK DK09752380.7T patent/DK2370441T3/da active
- 2009-11-18 BR BRPI0922303-7A patent/BRPI0922303B1/pt active IP Right Grant
- 2009-11-18 UA UAA201107950A patent/UA103504C2/ru unknown
- 2009-11-18 ES ES09752380T patent/ES2431279T3/es active Active
- 2009-11-18 PL PL09752380T patent/PL2370441T3/pl unknown
- 2009-11-18 CA CA2743976A patent/CA2743976C/en active Active
- 2009-11-18 SI SI200930769T patent/SI2370441T1/sl unknown
- 2009-11-18 MX MX2011005596A patent/MX2011005596A/es active IP Right Grant
- 2009-11-18 RU RU2011123703/04A patent/RU2507205C2/ru active
- 2009-11-18 KR KR1020117012049A patent/KR101359742B1/ko active Active
- 2009-11-18 HR HRP20131067AT patent/HRP20131067T1/hr unknown
- 2009-11-18 NZ NZ592076A patent/NZ592076A/en unknown
- 2009-11-18 WO PCT/EP2009/065354 patent/WO2010060836A1/en not_active Ceased
- 2009-11-18 PT PT97523807T patent/PT2370441E/pt unknown
- 2009-11-18 PE PE2011001019A patent/PE20110582A1/es active IP Right Grant
- 2009-11-18 MY MYPI20112399 patent/MY150837A/en unknown
- 2009-11-18 AU AU2009319123A patent/AU2009319123B2/en active Active
- 2009-11-18 SG SG2011038692A patent/SG171846A1/en unknown
- 2009-11-18 EP EP09752380.7A patent/EP2370441B1/en active Active
- 2009-11-18 JP JP2011537933A patent/JP5452608B2/ja active Active
- 2009-11-18 CN CN200980147825.3A patent/CN102227428B/zh active Active
- 2009-11-19 US US12/621,547 patent/US8227458B2/en active Active
- 2009-11-25 TW TW098140192A patent/TWI379833B/zh active
- 2009-11-26 AR ARP090104565A patent/AR074409A1/es active IP Right Grant
-
2011
- 2011-03-31 CO CO11039945A patent/CO6341478A2/es active IP Right Grant
- 2011-04-04 IL IL212122A patent/IL212122A/en active IP Right Grant
- 2011-04-28 CR CR20110220A patent/CR20110220A/es unknown
- 2011-05-10 ZA ZA2011/03419A patent/ZA201103419B/en unknown
- 2011-05-10 MA MA33827A patent/MA32781B1/fr unknown
- 2011-05-26 EC EC2011011089A patent/ECSP11011089A/es unknown
-
2012
- 2012-05-15 US US13/471,491 patent/US8461152B2/en active Active
-
2013
- 2013-10-24 CY CY20131100939T patent/CY1115435T1/el unknown
-
2018
- 2018-07-16 AR ARP180101972 patent/AR112338A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074409A1 (es) | Derivados de arilciclohexileteres de 5,6-dihidro-4h-2,3,5,10-b-tetraaza-benzo[e]azuleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en disfunciones sexuales y trastornos del snc, entre otras patologias. | |
| AR074354A1 (es) | Alquilciclohexileteres de dihidrotetraazabenzoazulenos, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| AR080927A1 (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas del receptor de v1a y un proceso para su obtencion | |
| AR074317A1 (es) | Espiro-5,6 dihidro -4h-2,3,5,10b-tetraaza-benzo(e)azulenos | |
| AR081374A1 (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos | |
| AR080733A1 (es) | Aril-ciclohexil-tetraazabenzo[e]azulenos, un proceso para su obtencion, una composicion farmaceutica que los contiene y su uso para la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el antagonismo del receptor de v1a | |
| AR066904A1 (es) | Pirrolopiridinas y pirazolopiridinas sustituidas como moduladores de las quinasas, una composicion farmaceutica que las incluye y su uso en el tratamiento del cancer | |
| AR080955A1 (es) | Aril-/heteroaril-ciclohexenil-tetraazabenzo(e)azulenos | |
| CO6150145A2 (es) | Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| CO2017011174A2 (es) | Derivados de etileno como moduladores metabotropicos de receptores de glutamato | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| AR081182A1 (es) | Heterobiaril-ciclohexil-tetraazabenzo[e]azulenos | |
| AR059512A1 (es) | Derivados de piridina -2- carboxamida | |
| AR071385A1 (es) | Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia. | |
| AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
| AR085149A1 (es) | Moduladores del receptor de glucagon | |
| AR084412A1 (es) | Compuestos de piridina fusionados, utiles como inhibidores de caseina quinasa, y las composiciones farmaceuticas que los contienen | |
| CO6260069A2 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa | |
| AR056560A1 (es) | Pirrolopiridinonas como moduladores cb1 | |
| AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
| ECSP14013296A (es) | Derivados de etinilo | |
| AR051290A1 (es) | Derivados de hidantoina sustituidas | |
| AR071925A1 (es) | Malonamidas como antagonistas de orexina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |